Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.08 USD | +5.83% | -1.40% | +36.63% |
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- With an enterprise value anticipated at 3.1 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+36.63% | 333M | C- | ||
-4.54% | 184B | C+ | ||
+0.32% | 107B | C | ||
-3.91% | 67.9B | A | ||
-5.33% | 46.49B | B- | ||
+11.25% | 45.81B | B- | ||
+6.38% | 42.55B | B+ | ||
+19.05% | 30.78B | B | ||
+16.53% | 26.11B | A- | ||
-4.90% | 23.9B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SGHT Stock
- Ratings Sight Sciences, Inc.